Orient Pharma Co (ROCO:4166) Growth Rank: 3 (As of Sep. 21, 2026) — 63% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4166 Orient Pharma Co Ltd ROCO:4166
69 GF Score
Price NT$24.50
GF Value NT$41.72
Valuation Significantly Undervalued
View Full Analysis

What is Orient Pharma Co Growth Rank?

Orient Pharma Co ROCO:4166 +0.20% 69 Growth Rank is 3 as of Sep. 21, 2026, which is 63% below its 10-year median of 8.00. GuruFocus rates ROCO:4166 with a GF Score™ of 69/100 and a GF Value™ of NT$41.72 (Significantly Undervalued).

Orient Pharma Co has the Growth Rank of 3.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Orient Pharma Co Growth Rank Related Terms

ROCO:4166 vs ZTS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orient Pharma Co Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's Growth Rank distribution charts can be found below:

* The bar in red indicates where Orient Pharma Co's Growth Rank falls into.


ROCO:4166
69GF Score
Orient Pharma Co Ltd ROCO:4166
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 3 mean?
Orient Pharma Co (ROCO:4166) has a Growth Rank of 3 as of Sep. 21, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Orient Pharma Co and its competitors. This is 63% below median its historical median of 8.00. Over the past decade, Orient Pharma Co's Growth Rank has ranged from 3.00 to 9.00.
Is Orient Pharma Co's Growth Rank too high?
Orient Pharma Co's current Growth Rank of 3 is 63% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. Overall, Orient Pharma Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's Growth Rank compare to ZTS?
Orient Pharma Co's Growth Rank of 3 can be compared against companies in the Drug Manufacturers industry. Historically, Orient Pharma Co's own Growth Rank has ranged from 3.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Orient Pharma Co and its competitors. Orient Pharma Co's current Growth Rank is 3, which is 63% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$41.72, compared to a current price of NT$24.50 — trading 41.3% below its estimated fair value. The current Growth Rank is 3, which is 63% below median its 10-year median of 8.00. Orient Pharma Co's overall GF Score™ is 69/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current Growth Rank is 3 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued. The current stock price of NT$24.50 is trading 41.3% below its estimated GF Value™ of NT$41.72. GuruFocus considers Orient Pharma Co to be Significantly Undervalued.

Key valuation signals for ROCO:4166:

  • Growth Rank: 3 (63% below median its 10-year median of 8.00)
  • GF Value™: NT$41.72 vs. price of NT$24.50 (41.3% below fair value)
  • GF Score™: 69/100

No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orient Pharma Co Business Description

Address No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
69GF Score

Get the complete analysis for ROCO:4166

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.50
Price
NT$41.72
GF Value